Cited 0 times in
CRY1 Regulates Chemoresistance in Association With NANOG by Inhibiting Apoptosis via STAT3 Pathway in Patients With Cervical Cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김재훈 | - |
dc.contributor.author | 조한별 | - |
dc.contributor.author | 한관희 | - |
dc.contributor.author | 윤희 | - |
dc.date.accessioned | 2021-12-28T17:26:11Z | - |
dc.date.available | 2021-12-28T17:26:11Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 1109-6535 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187098 | - |
dc.description.abstract | Background/aim: Cryptochrome 1 (CRY1), a core circadian gene, modulates circadian rhythm and carcinogenesis. Here, we investigated the role of CRY1 and its correlation with NANOG, a stem cell transcription factor, in cervical cancer. Materials and methods: Immunohistochemistry with tissue microarray was performed to evaluate CRY1 and NANOG expression in cervical cancer tissues, and their functional roles were assessed in cervical cancer cell lines. Results: CRY1 or NANOG was significantly over-expressed in cervical cancer tissues. Notably, combined over-expression of CRY1 and NANOG was correlated with a significantly poor OS and DFS and showed a stronger predictive value for chemoradiation response than each single protein. Furthermore, siCRY1 induced apoptosis, decreased NANOG expression, suppressed STAT3 signalling, and activated p53 signalling in cervical cancer cell lines. Conclusion: CRY1 and NANOG over-expression serves as a strong predictive biomarker for prognosis and chemoradiation response, and may be a new therapeutic target in patients with cervical cancer. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | International Institute of Anticancer | - |
dc.relation.isPartOf | CANCER GENOMICS & PROTEOMICS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | CRY1 Regulates Chemoresistance in Association With NANOG by Inhibiting Apoptosis via STAT3 Pathway in Patients With Cervical Cancer | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Obstetrics and Gynecology (산부인과학교실) | - |
dc.contributor.googleauthor | Gwan Hee Han | - |
dc.contributor.googleauthor | Julie Kim | - |
dc.contributor.googleauthor | Hee Yun | - |
dc.contributor.googleauthor | Hanbyoul Cho | - |
dc.contributor.googleauthor | Joon-Yong Chung | - |
dc.contributor.googleauthor | Jae-Hoon Kim | - |
dc.contributor.googleauthor | Stephen M Hewitt | - |
dc.identifier.doi | 10.21873/cgp.20291 | - |
dc.contributor.localId | A00876 | - |
dc.contributor.localId | A03921 | - |
dc.contributor.localId | A05548 | - |
dc.relation.journalcode | J03713 | - |
dc.identifier.eissn | 1790-6245 | - |
dc.identifier.pmid | 34697063 | - |
dc.subject.keyword | CRY1 | - |
dc.subject.keyword | NANOG | - |
dc.subject.keyword | apoptosis | - |
dc.subject.keyword | biomarker | - |
dc.subject.keyword | cervical cancer | - |
dc.subject.keyword | chemoradiation response | - |
dc.contributor.alternativeName | Kim, Jae Hoon | - |
dc.contributor.affiliatedAuthor | 김재훈 | - |
dc.contributor.affiliatedAuthor | 조한별 | - |
dc.contributor.affiliatedAuthor | 한관희 | - |
dc.citation.volume | 18 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 699 | - |
dc.citation.endPage | 713 | - |
dc.identifier.bibliographicCitation | CANCER GENOMICS & PROTEOMICS, Vol.18(6) : 699-713, 2021-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.